Sabby Management LLC Holding in Sarepta Therapeutics INC (SRPT) Raised as Share Price Rose

July 17, 2017 - By Stephen Andrade

Investors sentiment decreased to 1.07 in Q4 2016. Its down 0.45, from 1.52 in 2016Q3. It is negative, as 42 investors sold SRPT shares while 46 reduced holdings. 39 funds opened positions while 55 raised stakes. 38.63 million shares or 7.09% less from 41.57 million shares in 2016Q3 were reported. Laurion Management LP holds 0% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT) for 11,000 shares. Jefferies Gru Lc reported 839,342 shares. Nomura Holding holds 0% or 44,720 shares. Sabby Mgmt Limited holds 2.01M shares. Prelude Cap Mngmt Limited Co stated it has 3,724 shares or 0.01% of all its holdings. 1,215 were accumulated by Fortaleza Asset Inc. Pictet Asset Management Limited holds 54,200 shares or 0.01% of its portfolio. Rhumbline Advisers has invested 0% in Sarepta Therapeutics Inc (NASDAQ:SRPT). 213,246 were accumulated by Tiaa Cref Invest Mgmt Ltd Liability Corporation. Connecticut-based Cubist Systematic Strategies Ltd Com has invested 0.01% in Sarepta Therapeutics Inc (NASDAQ:SRPT). State Street Corp has 0.01% invested in Sarepta Therapeutics Inc (NASDAQ:SRPT). Blackrock Advisors reported 0.03% stake. Us Bancorp De stated it has 1,329 shares or 0% of all its holdings. Voya Inv Management Limited Co holds 19,699 shares or 0% of its portfolio. Elk Creek Ltd Com holds 0.59% or 316,463 shares in its portfolio.

Hal Mintz increased its stake in Sarepta Therapeutics Inc (SRPT) by 275.7% based on its latest 2016Q4 regulatory filing with the SEC. Sabby Management Llc bought 1.48M shares as the company’s stock rose 22.49% with the market. The hedge fund run by Hal Mintz held 2.01 million shares of the health care company at the end of 2016Q4, valued at $55.27 million, up from 536,282 at the end of the previous reported quarter. Sabby Management Llc who had been investing in Sarepta Therapeutics Inc for a number of months, seems to be bullish on the $1.92 billion market cap company. The stock decreased 0.85% or $0.3 during the last trading session, reaching $34.95. About 1.41 million shares traded or 7.63% up from the average. Sarepta Therapeutics Inc (NASDAQ:SRPT) has risen 96.82% since July 17, 2016 and is uptrending. It has outperformed by 80.12% the S&P500.

Sabby Management Llc, which manages about $835.79 million and $1.72 billion US Long portfolio, decreased its stake in Hess Corp (Call) by 1,157 shares to 902 shares, valued at $5.62 million in 2016Q4, according to the filing. It also reduced its holding in Monsanto Co (Call) by 5,294 shares in the quarter, leaving it with 313 shares, and cut its stake in Dynavax Technologies Corp (Call).

More notable recent Sarepta Therapeutics Inc (NASDAQ:SRPT) news were published by: which released: “Sarepta Therapeutics names new CEO” on June 28, 2017, also with their article: “Sarepta: Updates To Thesis” published on July 10, 2017, published: “Sarepta Therapeutics and Genethon Announce a Gene Therapy Research …” on June 21, 2017. More interesting news about Sarepta Therapeutics Inc (NASDAQ:SRPT) were released by: and their article: “Sarepta Therapeutics Appoints Douglas S. Ingram as President and Chief …” published on June 28, 2017 as well as‘s news article titled: “Sarepta Therapeutics: Say Hello To The New CEO” with publication date: July 17, 2017.

Sarepta Therapeutics Inc (NASDAQ:SRPT) Ratings Coverage

Among 24 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 17 have Buy rating, 1 Sell and 6 Hold. Therefore 71% are positive. Sarepta Therapeutics had 65 analyst reports since August 5, 2015 according to SRatingsIntel. The firm has “Neutral” rating by Piper Jaffray given on Friday, January 15. On Tuesday, August 25 the stock rating was upgraded by Vetr to “Buy”. The rating was maintained by Oppenheimer with “Buy” on Wednesday, June 7. The firm earned “Outperform” rating on Friday, October 28 by RBC Capital Markets. The stock of Sarepta Therapeutics Inc (NASDAQ:SRPT) has “Underperform” rating given on Friday, April 29 by Jefferies. Jefferies initiated the stock with “Hold” rating in Friday, October 23 report. The company was maintained on Monday, October 10 by Wedbush. The firm earned “Perform” rating on Tuesday, April 26 by Oppenheimer. As per Friday, August 7, the company rating was downgraded by Suntrust Robinson. The stock has “Reduce” rating by SunTrust on Tuesday, April 26.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: